Please use this identifier to cite or link to this item:
Title: Development of thermoresponsive ibuprofen nanoemulsion based-gel for potential topical use
Authors: Santos, Milena Lima Valério dos
Keywords: Nanoemulsion;Nanogel;Ibuprofen;Poloxamer 407
Issue Date: 6-Nov-2019
Publisher: Universidade Federal do Rio Grande do Norte
Citation: SANTOS, Milena Lima Valério dos. Development of thermoresponsive ibuprofen nanoemulsion based-gel for potential topical use. 2019. 26f. Trabalho de Conclusão de Curso (Graduação em Farmácia) - Departamento de Farmácia, Universidade Federal do Rio Grande do Norte, Natal, 2019.
Portuguese Abstract: Ibuprofen (IBF) is a non-steroidal anti-inflammatory drug (NSAID) that has analgesic, antipyretic and anti-inflammatory action, but is a poorly soluble drug. Aiming at improving the bioavailability of this drug, this study aimed to develop ibuprofen-containing nanoemulsions (NE) and gelatinized nanoemulsions (NEG) for possible topical use. Nanoemulsions were prepared using low energy technique at different surfactant concentrations. For the gelation of nanoemulsions a copolymer with thermoreversible properties was used in different proportions, being Poloxamer 407 (Pluronic F127®). The characteristics of both systems were evaluated with respect to average droplet size, polydispersion index and zeta potential. All samples presented nanometer droplet size and negative zeta potential; The polydispersion index values were variable. The selected nanoemulsion was translucent and had stable droplet size and polydispersion index over a period of 60 days. This system then received ibuprofen and the same characteristics were evaluated and the formulation was stable for 15 days. Afterwards, the empty and drug nanoemulsions were gelled with Pluronic F127® (F127) and maintained their stability for more than 40 days, maintaining their nanometric characteristics during the study. In addition, the in vitro release study showed that within 6 hours, it is possible that about 50% of the drug will be released, and after that release will remain constant. Thus, we can see that the development of NE can improve the bioavailability of IBF and that nanogels are a vehicle option for improving topical administration of this drug.
Other Identifiers: 20150118353
Appears in Collections:Farmácia

Files in This Item:
File Description SizeFormat 
Restricted Access Until 2022-01-01
Depósito de patente.
611,07 kBAdobe PDFView/Open    Request a copy

This item is licensed under a Creative Commons License Creative Commons